Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198310 | 1.00 | MAPK10 (0.47) | MAPK10MAPK1SIRT2SIRT1POLB | |
| SCHEMBL2870547 | 0.87 | RAB9A (0.48) | MAPK10SIRT2SIRT1L3MBTL1RAB9A | |
| SCHEMBL4331277 | 0.86 | MAPK1 (0.47) | MAPK1POLBL3MBTL1RAB9ASLC6A3 | |
| SCHEMBL4334013 | 0.84 | MAPK10 (0.43) | MAPK10MAPK1SIRT2SIRT1POLB | |
| SCHEMBL2864411 | 0.81 | MAPK10 (0.46) | MAPK10MAPK1SIRT2SIRT1MAPKAPK2 | |
| SCHEMBL4338881 | 0.80 | KDM4E (0.53) | MAPK10MAPK1POLBRAB9A | |
| SCHEMBL2862326 | 0.79 | KDM4E (0.46) | MAPK10SIRT2SIRT1MAPKAPK2PGK1 | |
| SCHEMBL4335941 | 0.76 | MAPT (0.49) | MAPK10MAPK1POLBRAB9A | |
| SCHEMBL4340978 | 0.76 | ALDH1A1 (0.46) | MAPK1POLBRECQLRAB9A | |
| SCHEMBL4329239 | 0.76 | MAPK1 (0.45) | MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK10 29/4885MAPK1 1/4885SIRT2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.